This drug has been approved for the treatment of multiple chronic inflammatory disorders.
This drug has been approved for the treatment of multiple chronic inflammatory disorders.
128 million adults in the U.S. are affected by hypertension and cardiovascular diseases.
Recent data from CWCI and WCRI, plus clinical concerns.
As part of a legislative-mandated study on work-related PTSD, the survey could influence regulator objectives for 2025.
A recent study involving the compound DOI showed promising results in mice.
A new NCCI report found that hotter and colder temperatures were associated with higher claims frequency, as much as 10% higher in some cases.
Tirzepatide was no longer considered in shortage, removing compounding privileges, until litigation remanded the decision.
Healthes’ AVP of Information Security, Tony Brown, discusses how cyber threats affect workers’ comp organizations.
NCCI hosted a recent webinar on opioid utilization, while Fair Health published a new Opioid Tracker tool to monitor state opioid data.
WCRI reports for Delaware and Philadelphia reported increases, matching patterns seen previously in other states.
